Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed prostate cancer pathologically proven by prostate biopsy~2. Prostate biopsy histology grade ≥ Gleason 3+3=6.~3. Patients considered as candidates for and medically fit to undergo prostatectomy~4. At least 10 days after most recent prostate biopsy~5. No known problems with peripheral IV or central line access~6. Able to tolerate urinary straight catheter placement~7. Patient is judged by the Investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits.~8. Patients or their legal representatives must have the ability to read, understand and provide written informed consent for the initiation of any study related procedures.~Exclusion Criteria:~1. Prior pelvic external beam radiation therapy or brachytherapy~2. Chemotherapy for prostate cancer~3. Hormone deprivation therapy~4. Investigational therapy for prostate cancer~5. Hemorrhagic cystitis or active prostatitis~6. Unable to lie flat during or tolerate PET/CT~7. Prior history of any other malignancy within the last 2 years, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer~8. No prostatectomy scheduled prior to follow-up visit (12 to 72 hours post imaging)~9. Serum creatinine \> 1.5 mg/dL or creatinine clearance \< 50 mL/min/1.73m2

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Patients with Primary Prostate Cancer (Type: EXPERIMENTAL): Patients will be imaged with 18F-DCFBC

Based on this trial design, predict the completion outcome and termination type (if applicable).